What key trials supported Polivy's FDA approval?
Polivy (polatuzumab vedotin-piiq), approved by the FDA in June 2019 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab (BR), relied primarily on the phase 2 GO29365 trial. This open-label study enrolled 80 patients (median age 64) who had received at least one prior CD20-directed regimen. Patients received Polivy 1.8 mg/kg plus BR every 21 days for up to eight cycles.[1][2]
How did Polivy plus BR perform against BR alone?
In the trial, Polivy-BR showed a complete response (CR) rate of 40% versus 18% for BR alone (80 patients randomized 1:1). Objective response rate was 45% versus 18%. Median duration of response was 12.4 months versus 4.7 months; median progression-free survival (PFS) was 7.6 months versus 2.0 months; median overall survival (OS) was 12.4 months versus 4.7 months. These improvements drove accelerated approval, with OS as the confirmatory endpoint.[1][2][3]
Who qualified for the trial and what were baseline risks?
Patients had ECOG 0-2, refractory disease or relapse within 12 months of frontline therapy, and no prior autologous stem cell transplant. Common adverse events with Polivy-BR included neutropenia (42%), thrombocytopenia (30%), anemia (22%), and peripheral neuropathy (40%, mostly grade 1-2). Fatal events occurred in 14% (Polivy-BR) versus 4% (BR), linked to infections and progressive disease.[1][2]
What expanded Polivy's approval later?
Full approval came in April 2023 after GO29365 confirmed OS benefit (stratified HR 0.73, median 12.4 vs. 4.7 months). A 2023 label update added frontline DLBCL use with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) based on phase 3 POLARIX trial (879 patients). POLARIX showed 27.3% PFS risk reduction at 2 years (HR 0.73) versus R-CHOP, with similar OS but higher peripheral neuropathy (43% vs. 34%).[3][4]
Any ongoing requirements or patent details?
Post-approval, Genentech monitors neuropathy and provides REMS-like education. No pediatric approval. Patent expiry for Polivy is around 2032-2035 per DrugPatentWatch.com listings, with challenges possible from biosimilar developers.[5][1]
Sources:
[1]: FDA Polivy Label (2023) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761121s020lbl.pdf
[2]: Sehn et al., Lancet Oncology (2019) - https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30749-4/fulltext
[3]: FDA Approval Summary (2023) - https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma
[4]: Tilly et al., NEJM (2022) - https://www.nejm.org/doi/full/10.1056/NEJMoa2115303
[5]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/POLIVY